Vertex lifts 2026 revenue outlook to $13.2B on robust CF and new product momentum
VRTX sits 29% above its 52-week low of $362.5.
Summary
Vertex posted Q2 2026 revenue of $3.33B (+12% YoY) and raised full-year guidance to $13.1–$13.2B, driven by CF products and rapid uptake of CASGEVY and JOURNAVX. The povetacicept PDUFA date is set for November 30, 2026, and the Crinetics acquisition is on track to close in Q3.
Key Events · Earnings and Guidance · VRTX
-
Q2 Revenue Beats, Guidance Raised
Total revenue of $3.33B (+12% YoY) exceeded expectations, and full-year 2026 guidance was raised to $13.1–$13.2B from $12.95–$13.1B, reflecting strong CF and non-CF product growth.
-
CASGEVY and JOURNAVX Accelerate
CASGEVY revenue reached $76M (78% QoQ growth) after FDA expanded its label to children 2+, and JOURNAVX revenue hit $50M (71% QoQ growth) with ~535K Q2 prescriptions and expanded payer coverage.
-
Povetacicept PDUFA Date Set
FDA assigned a PDUFA target action date of November 30, 2026, for povetacicept in IgA nephropathy, a potential first-in-class therapy for Vertex's emerging nephrology franchise.
-
Crinetics Acquisition on Track
The $10B acquisition of Crinetics Pharmaceuticals is expected to close in Q3 2026, adding rare endocrine diseases as a fifth therapeutic pillar.
Analysis · VRTX · Life Sciences
A strong second quarter saw revenue climb 12% to $3.33 billion, fueled by cystic fibrosis therapies and the accelerating launches of CASGEVY and JOURNAVX. Confidence in sustained momentum prompted management to raise full-year revenue guidance to $13.1–$13.2 billion. CASGEVY revenue surged 78% sequentially to $76 million after the FDA expanded its label to children as young as 2, while JOURNAVX grew 71% to $50 million on expanding payer coverage. A near-term catalyst arrives with the povetacicept PDUFA date of November 30, 2026, which could open a new nephrology franchise. Meanwhile, the pending $10 billion Crinetics acquisition, expected to close this quarter, adds a fifth therapeutic pillar. These results underscore Vertex's evolution from a CF-focused company into a diversified biotech with multiple growth drivers.
At the time of this filing, VRTX was trading at $467.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.5B. The 52-week trading range was $362.50 to $533.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.